Mitochondria (Marker for Human Cells, Granular RCC & Salivary Tumors) Antibody - Without BSA and Az
Mouse Monoclonal Antibody [Clone 113-1 ]
|Application ||IHC-P, IF|
|Isotype||Mouse / IgG1, kappa|
|Format||200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA at 1.0mg/ml.|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||Mitochondria (Marker for Human Cells, Granular RCC & Salivary Tumors) Antibody - Without BSA and Az is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This MAb recognizes a 60kDa antigen associated with the mitochondria in human cells. It can be used to stain mitochondria in cell or tissue preparations and can be used as a mitochondrial marker in subcellular fractions. It produces a spaghetti-like pattern in normal and malignant cells. This antibody is an excellent marker for human cells in xenographic model research. It reacts specifically with human cells, including neurons and embryonic stem cells. Immunostaining pattern with anti-mitochondrial MAb has been reported as a useful discriminatory adjunct in the complex differential diagnosis of granular renal cell tumors. Reportedly, this MAb facilitates the classification of salivary tumors.
Tickoo SK, Amin MB, Linden MD, Lee MW, Zarbo RJ. Antimitochondrial antibody (113-1) in the differential diagnosis of granular renal cell tumors. Am J Surg Pathol. 1997;21(8):922-30. | Vera-Sempere F, Vera-Sirera B. Usefulness of antimitochondrial antibody 113-1 in diagnosis and classification of salivary gland tumours with oncocytic differentiation. Acta Otorrinolaringol Esp. 2011;62(1):1-9
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.